Global Anti-obesity Drugs Market By Drug Type (Prescription Drugs, OTC Drugs), By Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs, Gut-Hormone Incretins- GLP-1 Agonists, Dual Agonists/GIP Agonists), By Route of Administration (Oral, Injectable), By Patient Type (Adults, Pediatrics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034
- Published date: June 2025
- Report ID: 151652
- Number of Pages: 341
- Format:
-
keyboard_arrow_up
-
-
- Novo Nordisk A/S Company Profile
- Eli Lilly and Company
- Hoffmann-La Roche AG
- Pfizer Inc Company Profile
- GSK plc
- Currax Pharmaceuticals LLC
- Boehringer Ingelheim International GmbH
- Amgen Inc.
- AstraZeneca Plc Company Profile
- Merck & Co., Inc.
- Zealand Pharma
- Takeda Pharmaceutical Co. Ltd
- Rhythm Pharmaceuticals, Inc.
- Vivus LLC
- Zydus Lifesciences Ltd.
- Gelesis Holdings Inc.
- Teva Pharmaceuticals Company Limited
- Hanmi Pharm.Co.,Ltd.
- Verdiva
- HK inno.N Corp.
- Dr. Reddys Laboratories Ltd Company Profile
- settingsSettings
Our Clients
- 151652
- June 2025
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
|
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
|---|---|---|---|
| e-Access | |||
| Report Library Access | |||
| Data Set (Excel) | |||
| Company Profile Library Access | |||
| Interactive Dashboard | |||
| Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
| Accessibility | 1 User | 2-5 User | Unlimited |
| Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
| Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
| Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |
